Home  »  Business   »  Finch Therapeutics Group Inc. Shares Are Down -94....

Finch Therapeutics Group Inc. Shares Are Down -94.19% Since The Beginning Of The Year

Finch Therapeutics Group Inc. (NASDAQ:FNCH) has seen 0.5 million shares traded in the recent trading session. The company, currently valued at $24.83M, closed the recent trade at $0.49 per share which meant it lost -$0.01 on the day or -3.09% during that session. The FNCH stock price is -1793.88% off its 52-week high price of $9.28 and 38.78% above the 52-week low of $0.30. If we look at the company’s 10-day average daily trading volume, we find that it stood at 84350.0 shares traded. The 3-month trading volume is 84.03K shares.

The consensus among analysts is that Finch Therapeutics Group Inc. (FNCH) is a Buy stock at the moment, with a recommendation rating of 1.70. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.4.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Finch Therapeutics Group Inc. (NASDAQ:FNCH) trade information

Sporting -3.09% in the red today, the stock has traded in the red over the last five days, with the highest price hit on Monday, 01/23/23 when the FNCH stock price touched $0.49 or saw a rise of 18.33%. Year-to-date, Finch Therapeutics Group Inc. shares have moved 4.50%, while the 5-day performance has seen it change -10.43%. Over the past 30 days, the shares of Finch Therapeutics Group Inc. (NASDAQ:FNCH) have changed -14.02%. Short interest in the company has seen 0.12 million shares shorted with days to cover at 2.23.

Wall Street analysts have a consensus price target for the stock at $11.00, which means that the shares’ value could jump 95.55% from the levels at last check today. The projected low price target is $3.00 while the price target rests at a high of $17.00. In that case, then, we find that the latest price level in today’s session is -3369.39% off the targeted high while a plunge would see the stock gain -512.24% from the levels at last check today.

Finch Therapeutics Group Inc. (FNCH) estimates and forecasts

Figures show that Finch Therapeutics Group Inc. shares have underperformed across the wider relevant industry. The company’s shares have lost -75.77% over the past 6 months, with this year growth rate of -51.35%, compared to 11.30% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2023 fiscal year revenue. Growth estimates for the current quarter are -25.00% and -52.40% for the next quarter. Revenue growth from the last financial year stood is estimated to be -83.80%.

2 analysts offering their estimates for the company have set an average revenue estimate of $750k for the current quarter. 2 have an estimated revenue figure of $1.9 million for the next quarter concluding in Dec 2022. Year-ago sales stood $11.34 million and $806k respectively for this quarter and the next, and analysts expect sales will shrink by -93.40% for the current quarter and 135.70% for the next.

Earnings growth for 2023 is a modest -77.80% while over the next 5 years, the company’s earnings are expected to increase by 41.70%.

FNCH Dividends

Finch Therapeutics Group Inc. is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Finch Therapeutics Group Inc. (NASDAQ:FNCH)’s Major holders

Insiders own 51.38% of the company shares, while shares held by institutions stand at 20.70% with a share float percentage of 42.58%. Investors are also buoyed by the number of investors in a company, with Finch Therapeutics Group Inc. having a total of 61 institutions that hold shares in the company. The top two institutional holders are Susquehanna International Group, LLP with over 1.77 million shares worth more than $5.03 million. As of Jun 29, 2022, Susquehanna International Group, LLP held 3.71% of shares outstanding.

The other major institutional holder is Avenir Management Company, LLC, with the holding of over 1.66 million shares as of Jun 29, 2022. The firm’s total holdings are worth over $4.72 million and represent 3.49% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. As of Jun 29, 2022, the former fund manager holds about 1.79% shares in the company for having 0.85 million shares of worth $2.42 million while later fund manager owns 0.12 million shares of worth $0.33 million as of Jun 29, 2022, which makes it owner of about 0.24% of company’s outstanding stock.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts